Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 10/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 10/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17609353 | 0.93 | GUCY1B2 (0.40) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL17609390 | 0.92 | GUCY1B2 (0.43) | ALDH1A1TDP1GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL17609394 | 0.91 | GUCY1A1 (0.43) | ALDH1A1TDP1NPC1RAB9AGUCY1A1 | |
| SCHEMBL17609379 | 0.90 | DPP4 (0.39) | ALDH1A1TDP1NPC1RAB9ATSHR | |
| SCHEMBL17609393 | 0.89 | GUCY1B2 (0.43) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL17609335 | 0.88 | GUCY1A1 (0.40) | ALDH1A1TDP1NPC1RAB9ATSHR | |
| SCHEMBL17609386 | 0.88 | ALDH1A1 (0.40) | ALDH1A1TDP1NPC1RAB9ATSHR | |
| SCHEMBL17609359 | 0.87 | ALDH1A1 (0.39) | ALDH1A1TDP1NPC1RAB9ATSHR | |
| SCHEMBL19505609 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TDP1NPC1RAB9ATSHR | |
| SCHEMBL17609480 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TDP1NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3194384-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042536-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042536-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | ALDH1A1 2631/4885TDP1 343/4885NPC1 1805/4885 |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GUCY1A2, GUCY1A1, GUCY1B2 | ALDH1A1 2139/4885TDP1 384/4885NPC1 2070/4885 |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | ALDH1A1 2631/4885TDP1 343/4885NPC1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.